[1]CurrentPatentAssignee:DRREDDY'SLABORATORIESLIMITED-US2005/272802,2005,A1Locationinpatent:Page/Pagecolumn2-3
[2]CurrentPatentAssignee:HETERODRUGSLIMITED-WO2004/85393,2004,A1Locationinpatent:Page4
[3]CurrentPatentAssignee:HETERODRUGSLIMITED-WO2004/85393,2004,A1Locationinpatent:Page5
[4]CurrentPatentAssignee:HETERODRUGSLIMITED-WO2004/85393,2004,A1Locationinpatent:Page5
110-16-7
189188-57-6
[1]CurrentPatentAssignee:GRUPOINSUD-EP1956002,2008,A1Locationinpatent:Page/Pagecolumn4
Title: A E Vickers, et al. In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76.
Title: T C Seerden, et al. Experimental pancreatitis disturbs gastrointestinal and colonic motility in mice: effect of the prokinetic agent tegaserod. Neurogastroenterol Motil. 2007 Oct;19(10):856-64.
Title: M D Crowell, et al. The effects of tegaserod, a 5-HT receptor agonist, on gastric emptying in a murine model of diabetes mellitus. Neurogastroenterol Motil. 2005 Oct;17(5):738-43.
Title: H-C Pan, et al. Tegaserod, a small compound mimetic of polysialic acid, promotes functional recovery after spinal cord injury in mice. Neuroscience. 2014 Sep 26;277:356-66.
Title: D T Beattie, et al. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60.
